Yusri Ali Elsayed

4.1k citations
40 papers · 3.2k · 3 hit papers · h-index 24

Impact in

  • Hematology top 2%
    • Multiple Myeloma Research and Treatments
  • Oncology top 2%
    • CAR-T cell therapy research

Papers in

    • Multiple Myeloma Research and Treatments 5
    • Blood Coagulation and Thrombosis Mechanisms 4
    • CAR-T cell therapy research 5
    • Peptidase Inhibition and Analysis 3

Yusri Ali Elsayed

40 papers receiving 3.1k citations

Yusri Ali Elsayed's Hit Papers

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study 2021 · 258 citations
2580+5+11Years since publication100200300400

Peers

Yusri Ali Elsayed
Comparison fields: 5 of 88
  • Hematology 576
  • Oncology 1.2k
  • Immunology 486
  • Pathology and Forensic Medicine 384
  • Genetics 212
Replace Thomas A. Puchalski with:
Thomas A. Puchalski United States
Peter B. Langmuir United States
Arvind Chaudhry United States
Emilie M.J. van Brummelen Netherlands
Frank Hartmann Germany
Martin Schreder Germany
Antoine Yver United States
Jason Claud Chandler United States
Hendrik De Raeve Belgium
Valerie Poulart United States
Yusri Ali Elsayed relative to Thomas A. Puchalski United States Thomas A. Puchalski's profile →
Citations per field
00.5×1.5×1.9×
Thomas A. Puchalski · 1×
Citations per year

Countries citing papers authored by Yusri Ali Elsayed

Since Specialization
Citations

This map shows the geographic impact of Yusri Ali Elsayed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusri Ali Elsayed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusri Ali Elsayed more than expected).

Fields of papers citing papers by Yusri Ali Elsayed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusri Ali Elsayed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusri Ali Elsayed. The network helps show where Yusri Ali Elsayed may publish in the future.

Co-authors

The 25 scholars most cited alongside Yusri Ali Elsayed, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yusri Ali Elsayed Line = papers co-authored together Yusri Ali Elsayed links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
Hit paper breakdown →
2009450
2 2005369
3
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Hit paper breakdown →
2012360
4 2017259
5
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Hit paper breakdown →
2021258
6 2020143
7 2009129
8 2020112
9 2013108
10 2005102
11 201197
12 200381
13 200873
14 201655
15 202451
16 200949
17 200148
18 202245
19 201139
20 202038

About Yusri Ali Elsayed

Yusri Ali Elsayed is a scholar working on Hematology, Oncology, Genetics, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 40 papers that have together received 3.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers), CAR-T cell therapy research (5 papers), Multiple Myeloma Research and Treatments (5 papers), Histone Deacetylase Inhibitors Research (4 papers), Blood Coagulation and Thrombosis Mechanisms (4 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Hematology (576 citations), Oncology (1.2k citations), Immunology (486 citations), Pathology and Forensic Medicine (384 citations) and Genetics (212 citations). Yusri Ali Elsayed has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Edward A. Sausville, Manish Monga, Brian L. Samuels, Axel Le Cesne, Jean‐Yves Blay, Margaret von Mehren, Claudia A. Lebedinsky, Johann Sebastian De Bono, Mary Louise Keohan and Chris H.M. Takimoto. Their work appears in journals such as Blood, Blood Advances, Clinical Cancer Research, Journal of Clinical Oncology and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact